Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy

Farwa Ali, Peter R. Martin, Hugo Botha, J. Eric Ahlskog, James Howard Bower, Joseph Y. Masumoto, Demetrius Maraganore, Anhar Hassan, Scott Daniel Eggers, Bradley F Boeve, David S Knopman, Daniel Drubach, Ronald Carl Petersen, Erika Driver Dunkley, Jay A Van Gerpen, Ryan Uitti, Jennifer Lynn Whitwell, Dennis W Dickson, Keith Anthony Josephs

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. Results: A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StatePublished - Jan 1 2019

Fingerprint

Progressive Supranuclear Palsy
Sensitivity and Specificity
Phenotype
Parkinsonian Disorders
Neurodegenerative Diseases
Signs and Symptoms
Primary Spontaneous Pneumothorax
Pathology
Brain

Keywords

  • MDS-PSP
  • NINDS-SPSP
  • progressive supranuclear palsy
  • PSP diagnostic criteria

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. / Ali, Farwa; Martin, Peter R.; Botha, Hugo; Ahlskog, J. Eric; Bower, James Howard; Masumoto, Joseph Y.; Maraganore, Demetrius; Hassan, Anhar; Eggers, Scott Daniel; Boeve, Bradley F; Knopman, David S; Drubach, Daniel; Petersen, Ronald Carl; Dunkley, Erika Driver; Van Gerpen, Jay A; Uitti, Ryan; Whitwell, Jennifer Lynn; Dickson, Dennis W; Josephs, Keith Anthony.

In: Movement Disorders, 01.01.2019.

Research output: Contribution to journalArticle

@article{bbffdfa765e147a19f798985046f31c2,
title = "Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy",
abstract = "Background: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. Results: A total of 129 patients were included, of whom 66 had PSP pathology (51{\%}). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9{\%}, compared with 45.5{\%} for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7{\%}, compared with 90.5{\%} for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.",
keywords = "MDS-PSP, NINDS-SPSP, progressive supranuclear palsy, PSP diagnostic criteria",
author = "Farwa Ali and Martin, {Peter R.} and Hugo Botha and Ahlskog, {J. Eric} and Bower, {James Howard} and Masumoto, {Joseph Y.} and Demetrius Maraganore and Anhar Hassan and Eggers, {Scott Daniel} and Boeve, {Bradley F} and Knopman, {David S} and Daniel Drubach and Petersen, {Ronald Carl} and Dunkley, {Erika Driver} and {Van Gerpen}, {Jay A} and Ryan Uitti and Whitwell, {Jennifer Lynn} and Dickson, {Dennis W} and Josephs, {Keith Anthony}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mds.27619",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy

AU - Ali, Farwa

AU - Martin, Peter R.

AU - Botha, Hugo

AU - Ahlskog, J. Eric

AU - Bower, James Howard

AU - Masumoto, Joseph Y.

AU - Maraganore, Demetrius

AU - Hassan, Anhar

AU - Eggers, Scott Daniel

AU - Boeve, Bradley F

AU - Knopman, David S

AU - Drubach, Daniel

AU - Petersen, Ronald Carl

AU - Dunkley, Erika Driver

AU - Van Gerpen, Jay A

AU - Uitti, Ryan

AU - Whitwell, Jennifer Lynn

AU - Dickson, Dennis W

AU - Josephs, Keith Anthony

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. Results: A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.

AB - Background: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. Methods: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. Results: A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. Conclusion: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.

KW - MDS-PSP

KW - NINDS-SPSP

KW - progressive supranuclear palsy

KW - PSP diagnostic criteria

UR - http://www.scopus.com/inward/record.url?scp=85061340783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061340783&partnerID=8YFLogxK

U2 - 10.1002/mds.27619

DO - 10.1002/mds.27619

M3 - Article

C2 - 30726566

AN - SCOPUS:85061340783

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -